FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137427440> ?p ?o ?g. }

• W3137427440 endingPage "728" @default.
• W3137427440 startingPage "728" @default.
• W3137427440 abstract "The randomized clinical trial (RCT) in oncology has evolved since its widespread adoption in the 1970s. In recent years, concerns have emerged regarding the use of putative surrogate end points, such as progression-free survival (PFS), and marginal effect sizes.To describe contemporary trends in oncology RCTs and compare these findings with earlier eras of RCT design and output.Retrospective cohort study of systemic therapy RCTs in breast, colorectal, and non-small cell lung cancer published in 7 major journals between 2010 and 2020. This strategy replicates prior work and allows for comparison of trends with RCTs published between 1995 to 2004 and 2005 to 2009.Data on RCT design, funding, results, and reporting were extracted from the published RCT report. Findings from the current period (2010-2020) were compared with data from RCTs published from 1995 to 2004 and 2005 to 2009. Descriptive and bivariate statistics were used to analyze temporal trends.The cohort included 298 RCTs (132 [44%] breast, 111 [37%] non-small cell lung cancer, 55 [19%] colorectal cancer). Experimental treatment included molecular inhibitor (171 of 298 [57%]), cytotoxic (83 of 298 [28%]), hormone (15 of 298 [5%]), and immune (24 of 298 [8%]) therapies. Sixty-nine percent (206 of 298) of RCTs were of palliative intent. The most common primary end point is now PFS; this has increased substantially over time (from 0% [0 of 167] to 18% [25 of 137] to 42% [125 of 298]; P < .001). Of 298 RCTs, 265 (89%) are now funded by industry (previously 95 of 167 [57%] and 107 of 137 [78%]; P < .001). Fifty-eight percent (173 of 298) of trials met their primary end point. Among positive trials, median improvement in overall survival and PFS was 3.4 and 2.9 months, respectively. More than one-third (117 of 298 [39%]) of reports used a professional medical writer; this increased substantially during the study period (from 3 of 27 [11%] in 2010 to 12 of 18 [67%] in 2020; P < .001).This cohort study suggests that contemporary oncology RCTs now largely measure putative surrogate end points and are almost exclusively funded by the pharmaceutical industry. The increasing role of medical writers warrants attention. To demonstrate that new cancer treatments are high value, the oncology community needs to consider the extent to which study end points and target effect size provide meaningful benefit to patients." @default.
• W3137427440 created "2021-03-29" @default.
• W3137427440 creator A5007770903 @default.
• W3137427440 creator A5033279700 @default.
• W3137427440 creator A5056009334 @default.
• W3137427440 creator A5059715152 @default.
• W3137427440 creator A5061745540 @default.
• W3137427440 creator A5080696424 @default.
• W3137427440 creator A5089899558 @default.
• W3137427440 date "2021-05-01" @default.
• W3137427440 modified "2023-10-16" @default.
• W3137427440 title "Evolution of the Randomized Clinical Trial in the Era of Precision Oncology" @default.
• W3137427440 cites W1570249624 @default.
• W3137427440 cites W2021158896 @default.
• W3137427440 cites W2023482608 @default.
• W3137427440 cites W2037624670 @default.
• W3137427440 cites W2097086646 @default.
• W3137427440 cites W2097995306 @default.
• W3137427440 cites W2102091262 @default.
• W3137427440 cites W2126251787 @default.
• W3137427440 cites W2131832494 @default.
• W3137427440 cites W2134119471 @default.
• W3137427440 cites W2136919572 @default.
• W3137427440 cites W2167123965 @default.
• W3137427440 cites W2415041554 @default.
• W3137427440 cites W2518192287 @default.
• W3137427440 cites W2530600980 @default.
• W3137427440 cites W2563003498 @default.
• W3137427440 cites W2586144993 @default.
• W3137427440 cites W2589693917 @default.
• W3137427440 cites W2621250710 @default.
• W3137427440 cites W2761792472 @default.
• W3137427440 cites W2775115920 @default.
• W3137427440 cites W2885324169 @default.
• W3137427440 cites W2894738161 @default.
• W3137427440 cites W2904154481 @default.
• W3137427440 cites W3058926349 @default.
• W3137427440 cites W3083327501 @default.
• W3137427440 cites W4234724180 @default.
• W3137427440 doi "https://doi.org/10.1001/jamaoncol.2021.0379" @default.
• W3137427440 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7995135" @default.
• W3137427440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33764385" @default.
• W3137427440 hasPublicationYear "2021" @default.
• W3137427440 type Work @default.
• W3137427440 sameAs 3137427440 @default.
• W3137427440 citedByCount "79" @default.
• W3137427440 countsByYear W31374274402021 @default.
• W3137427440 countsByYear W31374274402022 @default.
• W3137427440 countsByYear W31374274402023 @default.
• W3137427440 crossrefType "journal-article" @default.
• W3137427440 hasAuthorship W3137427440A5007770903 @default.
• W3137427440 hasAuthorship W3137427440A5033279700 @default.
• W3137427440 hasAuthorship W3137427440A5056009334 @default.
• W3137427440 hasAuthorship W3137427440A5059715152 @default.
• W3137427440 hasAuthorship W3137427440A5061745540 @default.
• W3137427440 hasAuthorship W3137427440A5080696424 @default.
• W3137427440 hasAuthorship W3137427440A5089899558 @default.
• W3137427440 hasBestOaLocation W31374274401 @default.
• W3137427440 hasConcept C121608353 @default.
• W3137427440 hasConcept C126322002 @default.
• W3137427440 hasConcept C141341695 @default.
• W3137427440 hasConcept C143998085 @default.
• W3137427440 hasConcept C168563851 @default.
• W3137427440 hasConcept C203092338 @default.
• W3137427440 hasConcept C2776256026 @default.
• W3137427440 hasConcept C526805850 @default.
• W3137427440 hasConcept C530470458 @default.
• W3137427440 hasConcept C71924100 @default.
• W3137427440 hasConcept C72563966 @default.
• W3137427440 hasConceptScore W3137427440C121608353 @default.
• W3137427440 hasConceptScore W3137427440C126322002 @default.
• W3137427440 hasConceptScore W3137427440C141341695 @default.
• W3137427440 hasConceptScore W3137427440C143998085 @default.
• W3137427440 hasConceptScore W3137427440C168563851 @default.
• W3137427440 hasConceptScore W3137427440C203092338 @default.
• W3137427440 hasConceptScore W3137427440C2776256026 @default.
• W3137427440 hasConceptScore W3137427440C526805850 @default.
• W3137427440 hasConceptScore W3137427440C530470458 @default.
• W3137427440 hasConceptScore W3137427440C71924100 @default.
• W3137427440 hasConceptScore W3137427440C72563966 @default.
• W3137427440 hasIssue "5" @default.
• W3137427440 hasLocation W31374274401 @default.
• W3137427440 hasLocation W31374274402 @default.
• W3137427440 hasLocation W31374274403 @default.
• W3137427440 hasLocation W31374274404 @default.
• W3137427440 hasOpenAccess W3137427440 @default.
• W3137427440 hasPrimaryLocation W31374274401 @default.
• W3137427440 hasRelatedWork W2089903975 @default.
• W3137427440 hasRelatedWork W2339228323 @default.
• W3137427440 hasRelatedWork W2372809030 @default.
• W3137427440 hasRelatedWork W2766672491 @default.
• W3137427440 hasRelatedWork W2902679640 @default.
• W3137427440 hasRelatedWork W2904759734 @default.
• W3137427440 hasRelatedWork W3138366407 @default.
• W3137427440 hasRelatedWork W4361907936 @default.
• W3137427440 hasRelatedWork W4362394812 @default.
• W3137427440 hasRelatedWork W4362394888 @default.
• W3137427440 hasVolume "7" @default.

• next